Cited by 842MicroRNA in disease regulationThyroid Cancer Diagnosis and TreatmentGenetic Associations and Epidemiology

Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma

Open access
Jazdzewski, Krystian, Murray, Elizabeth L., Franssila, Kaarle, Jarzab, Barbara, Schoenberg, Daniel R., de la Chapelle, Albert·2008·Proceedings of the National Academy of Sciences

Abstract

Although papillary thyroid carcinoma (PTC) displays strong heritability, no predisposing germ-line mutations have been found. We show that a common G/C polymorphism (rs2910164) within the pre-miR-146a sequence reduced the amount of pre- and mature miR-146a from the C allele 1.9- and 1.8-fold, respectively, compared with the G allele. This is matched by a similar decrease in the amount of each pre-miR generated from the corresponding pri-miR-146a in an in vitro processing reaction. The C allele also interfered with the binding of a nuclear factor to pre-miR-146a. The reduction in miR-146a led to less efficient inhibition of target genes involved in the Toll-like receptor and cytokine signaling pathway (TRAF6, IRAK1), and PTC1 (also known as CCDC6 or H4), a gene frequently rearranged with RET proto-oncogene in PTC. In an association study of 608 PTC patients and 901 controls, we found marked differences in genotype distribution of rs2910164 ( P = 0.000002), the GC heterozygous state being associated with an increased risk of acquiring PTC (odds ratio = 1.62, P = 0.000007), and both homozygous states protective with odds ratio = 0.42 for the CC genotype ( P = 0.003) and odds ratio = 0.69 for the GG genotype ( P = 0.0006). Moreover, 4.7% of tumors had undergone somatic mutations of the SNP sequence. Thus, our data suggest that a common polymorphism in pre-miR-146a affects the miR expression, contributes to the genetic predisposition to PTC, and plays a role in the tumorigenesis through somatic mutation. Preliminary evidence suggests that these effects are mediated through target genes whose expression is affected by the SNP status.

Integrity signals

Registry

Crossref · 10.1073/pnas.0802682105

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Jazdzewski, K., Murray, E. L., Franssila, K., Jarzab, B., Schoenberg, D. R., & de la Chapelle, A.
Affiliations
  • *Human Cancer Genetics Program, Comprehensive Cancer Center, Ohio State University, 850 Biomedical Research Tower, 460 West 12th Avenue, Columbus, OH 43210;
  • The Ohio State University (US)
  • Helsinki University Hospital (FI)
  • Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Wybrzeze Armii Krajowej 15, Gliwice 44-101, Poland
Venue
Proceedings of the National Academy of Sciences
Published
2008-05-20
Volume
105
Issue
20
Pages
7269-7274
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2081835397
Cited by
842
References
2
Citations by year
2026: 9 · 2025: 8 · 2024: 21 · 2023: 16 · 2022: 30 · 2021: 36 · 2020: 57 · 2019: 34 · 2018: 39 · 2017: 41 · 2016: 56 · 2015: 78 · 2014: 86 · 2013: 72 · 2012: 65
FWCI
22.09
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • American Thyroid Association
  • Ohio State University (CA16058, P30 CA16058)
  • National Cancer Institute (P-30-CA-16058, CA16058, P30CA016058)
  • National Institute of General Medical Sciences (GM 38277, R01GM038277)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
Keywords
papillary thyroid carcinoma, miR-146a, rs2910164, genetic susceptibility, microRNA expression, pri-miRNA processing, TRAF6, IRAK1, Toll-like receptor signaling, CCDC6, RET fusion, somatic mutations, nuclear factor binding, cancer susceptibility
MeSH terms
Proto-Oncogene Mas, Alleles, Carcinoma, Genotype, Humans, Mutation, Thyroid Neoplasms, Transfection, Cohort Studies, Case-Control Studies, Genetic Predisposition to Disease, Polymorphism, Single Nucleotide, MicroRNAs, Cell Line, Tumor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review